《2010美國肝病學會原發(fā)性硬化性膽管炎指南解讀》內(nèi)容預覽

This guideline has been approved by the American Asso-ciation for the Study of Liver Diseases and represents the position of the Association. These recommendations pro-vide a data-supported approach. They are based on the following:  formal review and analysis of the recently-published world literature on the topic (Medline search);American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines guideline policies, including the AASLD Policy on the Development and Use of Practice Guidelines and the American Gastroenterological Association Policy State-ment on Guidelines ; and  the experience of the au-thors in the specified topic.

Intended for use by physicians, these recommenda-tions suggest preferred approaches to the diagnostic, ther-apeutic and preventative aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case.

Specific recommendations are based on relevant pub-lished information. To more fully characterize the avail-able evidence supporting the recommendations, the AASLD Practice Guidelines Committee has adopted the classification used by the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) workgroup with minor modifications (Table 1).

The strength of recommendations in the GRADE system are classified as strong (class 1) or weak (class 2). The quality of evidence supporting strong or weak recommendations is designated by one of three levels: high (level A), mod-erate (level B), or low-quality (level C)

點擊下載完整版:《2010美國肝病學會原發(fā)性硬化性膽管炎指南解讀》